Skip to main content
. 2021 Dec 13;4(12):e2138550. doi: 10.1001/jamanetworkopen.2021.38550

Figure 3. Performance of the Prostate-Specific Membrane Antigen (PSMA) Nomogram, Staging Collaboration for Cancer of the Prostate (STAR-CAP) Stage Groups, Cancer of the Prostate Risk Assessment (CAPRA) Risk Groups, and Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in the Multi-institutional Cohort, as Assessed by the Concordance Indices.

Figure 3.

End points are biochemical recurrence (BCR) (A), distant metastasis (DM) (B), prostate cancer–specific mortality (PCSM) (C), and overall survival (OS) (D). Error bars represent 95% CIs.